MeiraGTx Secures $400M Investment from Oberland Capital

MeiraGTx Holdings (MGTX) has agreed to receive up to $400 million in funding from private investment firm Oberland Capital Management. The capital will support the development of MeiraGTx's gene therapy candidates, and shares rose approximately 7% in premarket trading.

By Dulan Lokuwithana, SA News Editor · Seeking Alpha · July 7, 2026, 12:08 UTC

MeiraGTx Secures $400M Investment from Oberland Capital

Tickers: $MGTX

Topics: biotech funding agreement gene therapy

Read the full article at Seeking Alpha

More World news

Rival Technologies Index Reveals Gen Z Financial Constraints Amidst Optimistic Outlook PR Newswire · November 12, 2026, 13:42 UTC
Canadian Cybersecurity Job Postings Rise While Entry-Level Opportunities Decline PR Newswire · November 12, 2026, 13:42 UTC
Klarna Appoints Robinhood's Chris Koegel as Chief Financial Officer Seeking Alpha · November 12, 2026, 13:35 UTC
Kyverna Therapeutics Reports Q3 GAAP EPS of -$0.68, Slightly Beating Estimates Seeking Alpha · November 12, 2026, 13:37 UTC
TelyRx Holdings Appoints Co-Founder Benjamin Atkins as Interim CEO Seeking Alpha · November 12, 2026, 13:38 UTC
Nvidia shares fall following analyst downgrades and reports of potential CEO leadership changes Seeking Alpha · November 12, 2026, 13:38 UTC
Technosylva Launches Technosylva Planning Application for Multi-Hazard Utility Risk Management PR Newswire · November 12, 2026, 13:38 UTC
PVH Corp. Announces Global Workforce Reduction of Approximately 4% Seeking Alpha · November 12, 2026, 13:34 UTC
Analysis Reveals 75% of Americans Reside in Car-Dependent Areas PR Newswire · November 12, 2026, 13:38 UTC
ASML Positioned for Potential Stock Split Amid Surging AI Demand and Record Results Motley Fool · November 12, 2026, 13:31 UTC